Nephrocare Health IPO opens; should you apply? Market guru Anil Singhvi decodes

IndiGo under SEBI radar for THIS reason; check share price update

Fresh Turbulence for IndiGo: CCI and Parliamentary panel tighten scrutiny, 10% flight cut ordered

Meesho Share Price: E-commerce stock surges 45% on debut on NSE, BSE – Buy, sell or hold? Anil Singhvi weighs in

Vidya Wires share price opens at Rs 52 on NSE, BSE—Massive subscription, muted listing

Aequs enters listed space at 13% premium; here's what Anil Singhvi suggests

Slight relief in Delhi’s air quality, yet pollution and cold hold firm

India-US trade talks set to resume on Wednesday, first since Trump 2.0 exited record shutdown

Gold & Silver Price Today: MCX outlook with key levels, trading strategy and fresh targets for traders

Stock Market Today: Sensex begins flat, Nifty tests 25,900; IndiGo, JSW Steel top losers

The Indian pharmaceutical sector is expected to achieve 7-9 per cent revenue growth in FY 2026, driven by strong domestic and European demand, despite a significant slowdown in its US market, a report said on Thursday.&nbsp;

Indian pharma companies' revenue to grow 7-9% in FY26 amidst US market risks: Report

Zee Business brings to you three companies on brokerages' watchlists this week. We have a pharmaceutical company, a logistics company, and a multinational company on our list. Check targets and other details.

From L&T To Divi's, Top Brokerage Calls This Week 

The company which started operations in India in 2008, currently has 8 manufacturing sites, including 5 in Ahmedabad with additional sites in Dahej, Hyderabad and Vizag, and commercial offices in Mumbai.&nbsp;

US-headquartered Amneal Pharmaceuticals to invest up to USD 200 mn in India to set up 2 plants

Pharma company Supriya Lifescience expects to double its revenue to Rs 1,000 crore in the next three years by venturing into higher-margin earning niche segments next fiscal, a senior company executive has said.&nbsp;

Supriya Lifescience expects to double revenue to Rs 1,000 crore in next 3 years 

The shares were disposed of at an average price of Rs 920 apiece, taking the transaction value to Rs 117 crore.

Small Cap World Fund sells shares worth Rs 117 crore in Ami Organics

Shares of Cipla Ltd (NSE: CIPLA) corrected in the D street on Nov 7. The downtrend follows despite the third-largest pharma company in India reporting a consolidated net profit increase of 12%.

Correction in Cipla stock, despite 12% consolidated net profit increase in Q2FY23

How is the new acquisition of Torrent Pharma-Curatio Health Care? How good is the new acquisition for Torrent Pharma? What will happen at Torrent Pharma today after the new acquisition? Know from Anil Singhvi.

Editors Take: How Is The New Acquisition Of Torrent Pharma-Curatio Health Care? Reveals Anil Singhvi

Sitaglyn and Siglyn offer an oral solution to the patients providing ease of convenience and better compliance, the company said in a regulatory filing.

Zydus Lifesciences launches generic version of Sitagliptin for type 2 diabetes

Pharma company Cipla has agreed to acquire an additional stake for nearly Rs 26 crore in digital tech company GoApptiv Private to raise its shareholding to 22.02 per cent, the company said on Monday.

Cipla to invest Rs 26 crore in GoApptiv to raise stake to 22%

Consolidated revenues of the drug firm, however, rose to Rs 3,019 crore in the quarter under review as compared to Rs 2,860 crore in the year-ago period.

Glenmark Pharma Q4FY22 Results: Consolidated profit dips 26% at Rs 173 cr, company announces dividend

Cipla Share Price:Brokerages are bullish on the Cipla shares and expects a 28 per cent upside in this stock. A healthy March quarter results will likely act as a trigger for the upside, they opined.&nbsp;

Cipla Share Price: After company reports healthy March quarter numbers, brokerages turn bullish on stock; recommend buy 

Value Pick: Strong India franchise, rich product pipeline makes Cipla shares lucrative; brokerages see 15% upside

pharma-company

The Indian pharmaceutical sector is expected to achieve 7-9 per cent revenue growth in FY 2026, driven by strong domestic and European demand, despite a significant slowdown in its US market, a report said on Thursday. 

Zee Business brings to you three companies on brokerages' watchlists this week. We have a pharmaceutical company, a logistics company, and a multinational company on our list. Check targets and other details.

The company which started operations in India in 2008, currently has 8 manufacturing sites, including 5 in Ahmedabad with additional sites in Dahej, Hyderabad and Vizag, and commercial offices in Mumbai. 

Pharma company Supriya Lifescience expects to double its revenue to Rs 1,000 crore in the next three years by venturing into higher-margin earning niche segments next fiscal, a senior company executive has said. 

The shares were disposed of at an average price of Rs 920 apiece, taking the transaction value to Rs 117 crore.

Zee Business

Home

Personal Finance

India

Economy

Tech

Auto

Markets

Jobs

Indian Railways

World

Videos

Photos

Pharma company News- Zee Business provides latest news on Pharma company, Pharma company news Today, Top News on Pharma company, update on Pharma company Stay updated with business news, breaking news headlines.

Pharma company Latest News- Top News on Pharma company, Update on Pharma company, Pharma company News Today, Breaking News Headlines, Business News | Zee Business

Pharma Company

Indian pharma companies' revenue to grow 7-9% in FY26 amidst US market risks: Report

From L&T To Divi's, Top Brokerage Calls This Week

US-headquartered Amneal Pharmaceuticals to invest up to USD 200 mn in India to set up 2 plants

Supriya Lifescience expects to double revenue to Rs 1,000 crore in next 3 years

Small Cap World Fund sells shares worth Rs 117 crore in Ami Organics

Correction in Cipla stock, despite 12% consolidated net profit increase in Q2FY23

RECOMMENDED

Nephrocare Health IPO opens; should you apply? Market guru Anil Singhvi decodes

IndiGo under SEBI radar for THIS reason; check share price update

Fresh Turbulence for IndiGo: CCI and Parliamentary panel tighten scrutiny, 10% flight cut ordered

Meesho Share Price: E-commerce stock surges 45% on debut on NSE, BSE – Buy, sell or hold? Anil Singhvi weighs in

Vidya Wires share price opens at Rs 52 on NSE, BSE—Massive subscription, muted listing

Aequs enters listed space at 13% premium; here's what Anil Singhvi suggests

Slight relief in Delhi’s air quality, yet pollution and cold hold firm

India-US trade talks set to resume on Wednesday, first since Trump 2.0 exited record shutdown

Gold & Silver Price Today: MCX outlook with key levels, trading strategy and fresh targets for traders

Stock Market Today: Sensex begins flat, Nifty tests 25,900; IndiGo, JSW Steel top losers

Editors Take: How Is The New Acquisition Of Torrent Pharma-Curatio Health Care? Reveals Anil Singhvi

Zydus Lifesciences launches generic version of Sitagliptin for type 2 diabetes

Cipla to invest Rs 26 crore in GoApptiv to raise stake to 22%

Glenmark Pharma Q4FY22 Results: Consolidated profit dips 26% at Rs 173 cr, company announces dividend

Cipla Share Price: After company reports healthy March quarter numbers, brokerages turn bullish on stock; recommend buy

Value Pick: Strong India franchise, rich product pipeline makes Cipla shares lucrative; brokerages see 15% upside

Top News

Nephrocare Health IPO opens; should you apply? Market guru Anil Singhvi decodes

IndiGo under SEBI radar for THIS reason; check share price update

Fresh Turbulence for IndiGo: CCI and Parliamentary panel tighten scrutiny, 10% flight cut ordered

Meesho Share Price: E-commerce stock surges 45% on debut on NSE, BSE – Buy, sell or hold? Anil Singhvi weighs in

Vidya Wires share price opens at Rs 52 on NSE, BSE—Massive subscription, muted listing

Aequs enters listed space at 13% premium; here's what Anil Singhvi suggests